Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine.
作者： Isabelle Trouilloud , Olivier Dubreuil , Tarek Boussaha , Céline Lepère , Bruno Landi
DOI: 10.1016/J.CLINRE.2011.02.002
关键词:
摘要: Summary Exocrine pancreatic cancer has a very poor prognosis. R0 resection of the tumor is to date only potentially curative approach, but less than 20% patients are eligible for surgery at diagnosis. Until recently, gemcitabine was standard treatment advanced and metastatic patients, since it shown more decade ago induce clinical benefit improve survival when compared weekly bolus 5-fluorouracil. In order patients’ outcome many trials have, during last 10 years, explored pharmacokinetic modulation combination therapies with other anti-cancer agents consistent negative results. It finally trial assessing efficacy chemotherapy without gemcitabine: FOLFIRINOX regimen, reported this year, that first time significant improvement in progression free overall survivals. parallel, testing new targeted these currently ongoing. After 10 years progress hope can be achieved been raised.
elsevier.com
sci-hub.se 参考文章(81)
Gilda da Cunha Santos, Neesha Dhani, Dongsheng Tu, Kayu Chin, Olga Ludkovski, Suzanne Kamel‐Reid, Jeremy Squire, Wendy Parulekar, Malcolm J Moore, Ming Sound Tsao, None, Molecular Predictors of Outcome in a Phase 3 Study of Gemcitabine and Erlotinib Therapy in Patients With Advanced Pancreatic Cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3 Cancer. ,vol. 116, pp. 5599- 5607 ,(2010) , 10.1002/CNCR.25393
T. Conroy, F. Desseigne, M. Ychou, M. Ducreux, O. Bouche, R. Guimbaud, Y. Becouarn, C. Montoto-Grillot, S. Gourgou-Bourgade, A. Adenis, , Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. Journal of Clinical Oncology. ,vol. 28, pp. 4010- 4010 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.4010
H A Burris, M J Moore, J Andersen, M R Green, M L Rothenberg, M R Modiano, M C Cripps, R K Portenoy, A M Storniolo, P Tarassoff, R Nelson, F A Dorr, C D Stephens, D D Von Hoff, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology. ,vol. 15, pp. 2403- 2413 ,(1997) , 10.1200/JCO.1997.15.6.2403
James J. Farrell, Hany Elsaleh, Miguel Garcia, Raymond Lai, Ali Ammar, William F. Regine, Ross Abrams, A. Bowen Benson, John Macdonald, Carol E. Cass, Adam P. Dicker, John R. Mackey, Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer Gastroenterology. ,vol. 136, pp. 187- 195 ,(2009) , 10.1053/J.GASTRO.2008.09.067
Stephen Cullinan, Charles G. Moertel, Harry S. Wieand, Allan J. Schutt, James E. Krook, John F. Foley, Brian D. Norris, Carl G. Kardinal, Loren K. Tschetter, John F. Barlow, A phase III trial on the therapy of advanced pancreatic carcinoma evaluations of the mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin Cancer. ,vol. 65, pp. 2207- 2212 ,(1990) , 10.1002/1097-0142(19900515)65:10<2207::AID-CNCR2820651007>3.0.CO;2-Y
Volker Heinemann, Stefan Boeck, Axel Hinke, Roberto Labianca, Christophe Louvet, Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer BMC Cancer. ,vol. 8, pp. 82- 82 ,(2008) , 10.1186/1471-2407-8-82
Donald A. Richards, Paul R. Kuefler, Carlos Becerra, Lalan S. Wilfong, Robert H. Gersh, Kristi A. Boehm, Feng Zhan, Lina Asmar, Scott P. Myrand, Rebecca R. Hozak, Luping Zhao, John F. Gill, Brian P. Mullaney, Coleman K. Obasaju, Steven J. Nicol, Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study. Investigational New Drugs. ,vol. 29, pp. 144- 153 ,(2011) , 10.1007/S10637-009-9307-8
F Di Costanzo, P Carlini, L Doni, B Massidda, R Mattioli, A Iop, E Barletta, L Moscetti, F Recchia, P Tralongo, S Gasperoni, Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). British Journal of Cancer. ,vol. 93, pp. 185- 189 ,(2005) , 10.1038/SJ.BJC.6602640
G P Stathopoulos, K Syrigos, G Aravantinos, A Polyzos, P Papakotoulas, G Fountzilas, A Potamianou, N Ziras, J Boukovinas, J Varthalitis, N Androulakis, A Kotsakis, G Samonis, V Georgoulias, A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. British Journal of Cancer. ,vol. 95, pp. 587- 592 ,(2006) , 10.1038/SJ.BJC.6603301
C N Mallinson, M O Rake, J B Cocking, C A Fox, M T Cwynarski, B L Diffey, G A Jackson, J Hanley, V J Wass, Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. BMJ. ,vol. 281, pp. 1589- 1591 ,(1980) , 10.1136/BMJ.281.6255.1589